Recommended antimicrobial therapy for common inpatient infections: a comparative review of guidelines across 51 hospital trusts in England. Issue 1154 (2nd October 2020)

• Record Type: Journal Article
• Authors: Pan, Daniel; Hills, George; Hamilton, Ashley Ryan; Nash, Tamsin; Hine, Thomas; Whitehorn, Sarah; Barlow, Gavin
• Is Part Of: Postgraduate medical journal. Volume 97:Issue 1154(2021)
• Page Start: 782
• Page End: 788
• Publication Date: 2020-10-02
• Subjects: Gastroenterology -- Gastrointestinal infections -- Thoracic medicine -- Respiratory infections -- Urology -- Urinary tract infections; Medicine -- Periodicals; 610
• DOI: 10.1136/postgradmedj-2020-138452
• Languages: English
• ISSNs: 0032-5473

Abstract

ABSTRACT: Background: The number of different antimicrobial recommendations between hospital trusts for the same indication in England is unknown. Aim: We aimed to evaluate the heterogeneity of antimicrobial recommendations for seven common inpatient infections across hospital trusts in England and evaluate changes to recommendations following introduction of national (National Institute for Healthcare and Excellence, NICE) and international (WHO) antimicrobial guidelines. Methods: Guidelines published on the MicroGuide smartphone application were collected from December 2017 to February 2018 and re-evaluated between December 2019 and February 2020. The following indications were assessed: community-acquired pneumonia (CAP) CURB65 score ≥3, hospital-acquired pneumonia (HAP), infective exacerbation of chronic obstructive pulmonary disease (iCOPD), cellulitis, uncomplicated urinary tract infection (uUTI), intra-abdominal infection (IAI) and sepsis of unknown source (SUS). On follow-up, compliance against WHO WATCH antibiotic and NICE recommendations was evaluated. Results: Guidelines were obtained predominantly from England. Antibiotic regimens between hospitals became increasingly diverse across indications in the following order: uUTI, cellulitis, iCOPD, CAP, HAP, IAI and SUS. A piperacillin/tazobactam-based regimen was recommended in HAP (59%), SUS (39%) and IAI (30%). After 2 years, 107 changes were made to 357 antibiotic regimen recommendations; the overall number of regimens using piperacillin–tazobactam and WHO WATCH antibiotics remained similar. Compliance of recommendations with NICE guidelines as follows: iCOPD (100% adherent), uUTI (98%), cellulitis (90%), CAP (43%) and HAP (27%). Conclusion: The heterogeneity of antibiotic recommendations increased as the indicated infection was more severe, with broader underlying bacterial causes. Piperacillin–tazobactam remains favoured in antibiotic regimens, despite not recommended in WHO and NICE guidance.